standard of care in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Cao, 2020 (REV) 1.40 [0.71; 2.76]
REMAP-CAP (lopinavir/ritonavir only), 2020 (REV) 1.20 [0.94; 1.55]
1.23 [0.97 ; 1.55 ] Cao, 2020 (REV), REMAP-CAP (lopinavir/ritonavir only), 2020 (REV) 2 0% 844 moderate not evaluable deaths (time to event analysis only)detailed results REMAP-CAP (lopinavir/ritonavir only), 2020 (REV) 1.20 [0.94; 1.55]
1.20 [0.94 ; 1.55 ] REMAP-CAP (lopinavir/ritonavir only), 2020 (REV) 1 0% 645 NA not evaluable clinical improvementdetailed results Cao, 2020 (REV) 0.76 [0.55; 1.07]
0.76 [0.55 ; 1.07 ] Cao, 2020 (REV) 1 0% NA not evaluable clinical improvement (14-day)detailed results Cao, 2020 (REV) 0.51 [0.29; 0.92]
REMAP-CAP (lopinavir/ritonavir only), 2020 (REV) 1.18 [0.89; 1.55]
0.81 [0.36 ; 1.82 ] Cao, 2020 (REV), REMAP-CAP (lopinavir/ritonavir only), 2020 (REV) 2 84% 844 moderate not evaluable clinical improvement (28-day)detailed results Cao, 2020 (REV) 0.63 [0.33; 1.20]
0.63 [0.33 ; 1.20 ] Cao, 2020 (REV) 1 0% 199 NA not evaluable clinical improvement (7-day)detailed results Cao, 2020 (REV) 0.32 [0.06; 1.61]
0.32 [0.06 ; 1.61 ] Cao, 2020 (REV) 1 0% 199 NA not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 (REV) 0.76 [0.55; 1.07]
0.76 [0.55 ; 1.07 ] Cao, 2020 (REV) 1 0% NA not evaluable hospital dischargedetailed results REMAP-CAP (lopinavir/ritonavir only), 2020 (REV) 1.20 [1.00; 1.45]
1.20 [1.00 ; 1.45 ] REMAP-CAP (lopinavir/ritonavir only), 2020 (REV) 1 0% 645 NA not evaluable serious adverse eventsdetailed results Cao, 2020 (REV) 1.91 [0.99; 3.68]
REMAP-CAP (lopinavir/ritonavir only), 2020 (REV) 0.64 [0.29; 1.42]
1.13 [0.39 ; 3.31 ] Cao, 2020 (REV), REMAP-CAP (lopinavir/ritonavir only), 2020 (REV) 2 77% 811 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-10 10:00 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
